

Coway (021240.KS)

Company Comment | Aug 5, 2015

Key investment points: Profitability improving and dividend yield high

Coway's 2Q15 earnings came in line with our expectations. Despite investor concerns towards growing competition affecting the health appliance division, the play successfully defended its profit levels thanks to solid sales growth at the health appliance division. We expect both the launching of a water purifier business (featuring its flagship brand 'Coway') in China and a high dividend yield (around 3% based on the current share price) to catalyze the shares in 2H15. Backed by these positives, we raise our target price to W125,000.

2Q15 results: Profit grows rapidly and at pace we expected

- On an IFRS non-consolidated basis, Coway announced 2Q15 sales of W527.5bn (up 0.8% y-y) and operating profit of W111.7bn (up 14.4% y-y), with both numbers meeting consensus and our estimates. While the firm's 2Q15 sales growth (y-y) was somewhat sluggish (attributable to a contraction at its overseas ODM business—sales started slowing in 1Q15 (sales down 55% y-y in 1Q15)), sales at the health appliance division (the company's core business) rose 6.2% y-y. In detail, the play's operating profit rose 14.4% y-y, led by sales volume growth on: 1) new product effects; and 2) strengthened channel competitiveness. Despite investor concerns towards competition affecting the health appliance division, Coway continues to secure new customers thanks to diversification of both its products and sales channels.
- The company's 2Q15 rental cancellation ratio exceeded 1%. However, considering the loss rate on rental asset disposals (rental cancellation ratio and loss rate on rental asset disposals are key profit determinants for the company), we believe that its operating profit will continue to mark solid growth going forward.

Growth catalysts: Flagship Coway business in China and favorable sales at core business

- Coway is planning to launch a water purifier business (featuring its flagship 'Coway' brand) in China. We believe that the firm will present a detailed strategic blueprint for this new venture in the near future.
- Also, the play is engaged in expanding its domestic sales channels—its products are now for sale at the electronics chain Hi-Mart and domestic duty free stores (DFSs).


Dividend yield high—catalyst for valuation hike

We stick to our Buy rating and raise our target price from W110,000 to W125,000. Considering the recent sales volume growth at the company's core business, we raised our 2016 and 2017 operating profit estimates by 8~9% for each year. Our new target price is equivalent to a 2016F P/E of 26x, the same as the average for the consumer staples segment. Our upbeat assessment is based on the following: 1) Coway has a unique business model (sustainable subscriber-based rental business); 2) the firm possesses a unique earnings structure (relatively unaffected by the phase of the economic cycle); and 3) there exists anticipation towards an increase in dividends.

Buy (maintain)

TP	W125	5,000 (raise)
CP ('15/08	/04)	W98,600
Sector	Co	onsumer goods
Kospi		2,027.99
Kosdaq		730.03
Market cap	(common)	US\$6,505.13mn
Outstanding	shares(co	mmon) 77.1mn
52W high ('	15/04/07)	W103,500
low ('1	5/01/08)	W78,900
Average tra	ding value(60D) US\$11.54mn
Dividend yie	eld(2014)	2.4%
Foreign own	nership	53.7%







Cookie Han, Analyst 822)768-7480, cookie@nhwm.com

Hyojin Lee, RA 822)768-7684, hyojin.lee@nhwm.com

(Units: Wbn, won, %)

2Q15 review									(Units:	Wbn, %)
	2011	2014	4044		2Q15P					20455
	2Q14	3Q14	4Q14	1Q15	Actual	у-у	q-q	Estimate	Consensus	3Q15E
Sales	523	496	500	506	527	0.8	4.2	531	539	535
Operating profit	98	97	93	99	112	14.4	2.5	109	107	112
Operating margin	18.7	19.5	18.7	19.5	21.2			20.5	19.8	21.0
Pretax profit	87	88	67	98	111	28.5	13.3	108	106	131
Net profit	65	66	45	75	85	30.4	13.3	78	79	101

Note: IFRS non-consolidated basis; Source: Coway, FnGuide, NH I&S research center estimates

DCF-based target price of W125,000


2014 2015E 2016F 2017F 2018F 2019F 2020F EBIT 377 426 479 513 640 685 692 NOPLAT 281 314 353 471 504 509 378 DEP+AMOR 200 163 179 189 198 209 220 CAPEX 276 178 238 224 231 249 256 FCF 233 305 291 350 452 476 481 Discount factor 0.94 0.88 0.83 0.78 0.73 0.68 PV of FCF 286 256 289 351 347 328 Sum of PV 1,857 Continuing Value Noplat as of 2019 509 [Key assumptions] 2.0 g=2.0% g ROIC Rf=4.0% 29.9 CV at the end of 2019 10,753 Rp=6.0% discount factor 0.68 Beta=0.7 PV of Continuing Value 7,346 Equity Value 9,260 +net debt 57 -minority interest 0 -Preferred Stock 0 mid-year adjust factor 1.04 **Current Equity Value** 9,619 Per share Value 125,000 shares outstanding 77,125 Present price 98,600 Upside (%) 26.8


Source: NH I&S Research Center estimates

Earnings forecasts	(IFRS non-consolidate	ed)		(Units: V	/bn, won, x, %)
		2014	2015E	2016F	2017F
Sales	- Revised	2,013.6	2,111.3	2,240.5	2,343.9
	- Previous		2,065.4	2,090.1	2,172.5
	- Change		2.2	7.2	7.9
Operating profit	- Revised	377.5	426.4	479.1	512.8
	- Previous		425.6	442.5	470.6
	- Change		0.2	8.3	9.0
Operating margin (revised	1)		20.2	21.4	21.9
EBITDA		577.0	589.4	658.4	702.0
Net profit (excl minority in	terests)	242.9	332.0	368.3	391.3
EPS	- Revised	3,150	4,305	4,775	5,074
	- Previous		4,298	4,429	4,677
	- Change		0.2	7.8	8.5
P/E		26.7	22.9	20.6	19.4
P/B		6.1	6.4	5.8	5.4
EV/EBITDA		11.4	12.9	11.4	10.6
ROE		24.0	29.5	29.5	28.7

Note: Operating profit = sales – (COGS + SG&A expenses) Source: NH I&S Research Center estimates







Source: DataGuide Pro

Earnings forecasts

(Units: Wbn, %)

	1Q14	2Q14	3Q14	4Q14	1Q15	2Q15P	3Q15E	4Q15F	2014	2015E	2016F
Sales	495	523	496	500	506	527	535	543	2,014	2,111	2,241
Rental	342	347	353	359	363	387	394	401	1,401	1,546	1,634
Membership	44	46	47	47	46	45	49	50	183	191	202
Lump-sum sales	26	37	32	27	30	41	32	27	122	131	137
Exports	45	56	33	33	33	39	30	30	167	132	136
Cosmetics	21	22	17	20	23	21	15	21	80	80	83
Other	15	15	15	14	11	9	15	14	58	48	48
Sales growth	6.4	5.3	1.4	3.6	2.3	0.8	7.9	8.6	4.1	4.9	6.1
Rental	4.6	4.5	5.3	5.8	6.1	11.7	11.8	11.7	5.0	10.4	5.7
Membership	2.6	7.0	8.6	7.4	4.9	-0.8	4.5	7.0	6.4	3.9	6.2
Lump-sum sales	-29.6	-21.8	-10.4	-9.1	16.4	10.7	1.5	1.5	-18.5	7.5	5.0
Exports	43.6	25.1	-13.0	9.3	-27.0	-30.0	-10.0	-10.0	15.8	-21.2	3.0
Cosmetics	17.4	0.5	3.6	1.1	10.5	-5.3	-10.0	3.0	5.3	-0.1	3.0
Other	63.4	98.4	-31.0	-31.1	-28.2	-38.6	0.0	0.0	1.1	-17.3	0.0
Gross profit	326	343	334	338	347	361	361	367	1,340	1,436	1,516
Gross margin	65.8	65.5	67.2	67.7	68.5	68.4	67.4	67.7	66.6	68.0	67.7
Operating profit	90	98	97	93	99	112	112	103	377	426	479
Growth	29.7	23.0	-0.1	6.4	10.2	14.4	15.8	11.1	13.3	13.0	12.4
Operating margin	18.1	18.7	19.5	18.7	19.5	21.2	21.0	19.1	18.7	20.2	21.4

Source: Coway, NH I&S Research Center estimates

2014/12A 2015/12E 2016/12F 2017/12F

20.6

22.2 15.7

5.8

19.4

20.9

14.8

5.4

22.9

24.6

17.4

6.4

STATEMENT OF COMPREHENSIVE INCOME

(Wbn)	2014/12A	2015/12E	2016/12F	2017/12F	
Sales	2,014	2,111	2,241	2,344	Price/Earning (X)
Growth (%)	4.1	4.9	6.1	4.6	PER (High,X)
COGS	673	676	724	753	PER (Low,X)
Gross Profit	1,340	1,436	1,516	1,591	Price/ Book Value (X)
Gross margin (%)	66.6	68.0	67.7	67.9	PBR (High,X)
SG&A	963	1,009	1,037	1,078	PBR (Low,X)
Operating Income	377	426	479	513	Price/ Gross Cash Flow
Growth (%)	13.3	13.0	12.4	7.0	Price/ Sales (X)
Operating margin (%)	18.7	20.2	21.4	21.9	PER/ EPS growth (X)
EBITDA	577	589	658	702	PER/ EBITPS growth (2
Non-Operating Profits	-48	25	22	20	PER/ EBITDAPS growt
Financial Income(Costs)	-9	15	14	14	EV/ EBITDA (X)
Other Non-Operating Profits	-9	0	0	0	EV/ EBIT (X)
Gains(Losses) in Associates, Subsidiaries and JVs	-31	10	8	6	Enterprise Value (Wbn)
Pre-tax Profit from Cont. Op.	330	452	501	532	EPS CAGR (3-Yr) (%)
Income Taxes	87	120	133	141	EBITPS CAGR (3-Yr) (
Profit from Continuing Op.	243	332	368	391	EBITDAPS CAGR (3-Y
Net Profit	243	332	368	391	EBITPS (W)
Growth (%)	-4.1	36.7	10.9	6.3	EBITDAPS (W)
Net margin (%)	12.1	15.7	16.4	16.7	Fully diluted EPS (W)
Net Profit of Parent	243	332	368	391	BVPS (W)
Net Profit to Non-Controlling	0	0	0	0	CFPS (W)
Other Comprehensive Income	-8	0	0	0	Sales PS (W)
Total Comprehensive Income	235	332	368	391	DPS (W)
CASH FLOV	V STAT	EMEN			

2014/12A	2015/12E	2016/12F	2017/12F
498	446	497	551
243	332	368	391
200	163	179	189
31	0	0	0
-4	0	0	0
40	0	0	0
653	619	684	725
-57	-54	-55	-33
-269	-220	-238	-223
8	0	0	0
-276	-178	-238	-224
31	-2	-2	-2
223	268	258	327
230	226	259	328
-325	-147	-197	-255
0	0	0	0
-325	-147	-197	-255
-96	79	62	73
106	185	247	320
57	-15	-70	-136
	498 243 200 31 -4 40 653 -57 -269 8 -276 31 223 230 -325 -96 106	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

PBR (High,X)	6.9	6.8	6.3	5.8
PBR (Low,X)	4.6	4.8	4.4	4.1
Price/ Gross Cash Flow (X)	10.0	12.3	11.1	10.5
Price/ Sales (X)	3.2	3.6	3.4	3.2
PER/ EPS growth (X)	1.6	1.7	1.7	1.9
PER/ EBITPS growth (X)	2.5	1.6	1.6	1.9
PER/ EBITDAPS growth (X)	4.0	1.8	1.9	2.1
EV/ EBITDA (X)	11.4	12.9	11.4	10.6
EV/ EBIT (X)	17.4	17.8	15.7	14.6
Enterprise Value (Wbn)	6,551	7,589	7,534	7,468
EPS CAGR (3-Yr) (%)	17.2	13.3	11.9	10.1
EBITPS CAGR (3-Yr) (%)	10.8	14.5	12.6	10.5
EBITDAPS CAGR (3-Yr) (%)	6.8	12.5	10.7	9.1
EBITPS (W)	4,895	5,528	6,211	6,649
EBITDAPS (W)	7,482	7,642	8,537	9,102
Fully diluted EPS (W)	3,150	4,305	4,775	5,074
BVPS (W)	13,732	15,483	16,947	18,356
CFPS (W)	8,462	8,031	8,874	9,400
Sales PS (W)	26,109	27,376	29,051	30,391
DPS (W)	2,000	2,652	3,438	3,806
RIM	& EVA			
	2014/124	2015/125	2016/12F	2017/125
RIM	2014/12A	2015/12E	2010/121	2017/121
RIM Spread (FROE-COE) (%)	16.4	2013/122	2010/121	2017/121
Spread (FROE-COE) (%)	16.4	21.3	22.9	22.1
Spread (FROE-COE) (%) Residual Income	16.4 166.5	21.3	22.9	22.1
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W)	16.4 166.5	21.3	22.9	22.1
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA	16.4 166.5 118,769	21.3 262.2	22.9 290.8	22.1 306.9
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital	16.4 166.5 118,769 1,018.6 280.9 28.5	21.3 262.2 1,082.2 314.2 29.9	22.9 290.8 1,139.5 352.9 31.8	22.1 306.9 1,181.9 377.7 32.5
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital NOPAT	16.4 166.5 118,769 1,018.6 280.9 28.5 22.3	21.3 262.2 1,082.2 314.2 29.9 23.4	22.9 290.8 1,139.5 352.9 31.8 26.3	22.1 306.9 1,181.9 377.7 32.5 27.0
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital NOPAT ROIC (%) ROIC - WACC (%) EVA	16.4 166.5 118,769 1,018.6 280.9 28.5	21.3 262.2 1,082.2 314.2 29.9	22.9 290.8 1,139.5 352.9 31.8	22.1 306.9 1,181.9 377.7 32.5
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital NOPAT ROIC (%) ROIC - WACC (%) EVA DCF	16.4 166.5 118,769 1,018.6 280.9 28.5 22.3 227.6	21.3 262.2 1,082.2 314.2 29.9 23.4 252.7	22.9 290.8 1,139.5 352.9 31.8 26.3 299.7	22.1 306.9 1,181.9 377.7 32.5 27.0 319.3
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital NOPAT ROIC (%) ROIC - WACC (%) EVA DCF EBIT	16.4 166.5 118,769 1,018.6 280.9 28.5 22.3 227.6 377.5	21.3 262.2 1,082.2 314.2 29.9 23.4 252.7 426.4	22.9 290.8 1,139.5 352.9 31.8 26.3 299.7 479.1	22.1 306.9 1,181.9 377.7 32.5 27.0 319.3 512.8
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital NOPAT ROIC (%) ROIC - WACC (%) EVA DCF EBIT + Depreciation/Amortization	16.4 166.5 118,769 1,018.6 280.9 28.5 22.3 227.6 377.5 200	21.3 262.2 1,082.2 314.2 29.9 23.4 252.7 426.4 163	22.9 290.8 1,139.5 352.9 31.8 26.3 299.7 479.1 179	22.1 306.9 1,181.9 377.7 32.5 27.0 319.3 512.8 189
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital NOPAT ROIC (%) ROIC - WACC (%) EVA DCF EBIT + Depreciation/Amortization - CAPEX	16.4 166.5 118,769 1,018.6 280.9 28.5 22.3 227.6 377.5 200 -275.7	21.3 262.2 1,082.2 314.2 29.9 23.4 252.7 426.4 163 -178.4	22.9 290.8 1,139.5 352.9 31.8 26.3 299.7 479.1 179 -238.5	22.1 306.9 1,181.9 377.7 32.5 27.0 319.3 512.8 189 -224.1
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital NOPAT ROIC (%) ROIC - WACC (%) EVA DCF EBIT + Depreciation/Amortization - CAPEX - Incr. (Decr.) in Working Capital	16.4 166.5 118,769 1,018.6 280.9 28.5 22.3 227.6 377.5 200 -275.7 -31.1	21.3 262.2 1,082.2 314.2 29.9 23.4 252.7 426.4 163 -178.4 -6.7	22.9 290.8 1,139.5 352.9 31.8 26.3 299.7 479.1 179 -238.5 1.8	22.1 306.9 1,181.9 377.7 32.5 27.0 319.3 512.8 189 -224.1 -7.6
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital NOPAT ROIC (%) ROIC - WACC (%) EVA DCF EBIT + Depreciation/Amortization - CAPEX - Incr. (Decr.) in Working Capital Free Cash Flow for Firm	16.4 166.5 118,769 1,018.6 280.9 28.5 22.3 227.6 377.5 200 -275.7	21.3 262.2 1,082.2 314.2 29.9 23.4 252.7 426.4 163 -178.4	22.9 290.8 1,139.5 352.9 31.8 26.3 299.7 479.1 179 -238.5	22.1 306.9 1,181.9 377.7 32.5 27.0 319.3 512.8 189 -224.1
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital NOPAT ROIC (%) ROIC - WACC (%) EVA DCF EBIT + Depreciation/Amortization - CAPEX - Incr. (Decr.) in Working Capital Free Cash Flow for Firm WACC	16.4 166.5 118,769 1,018.6 280.9 28.5 22.3 227.6 377.5 200 -275.7 -31.1 233.1	21.3 262.2 1,082.2 314.2 29.9 23.4 252.7 426.4 163 -178.4 -6.7 304.7	22.9 290.8 1,139.5 352.9 31.8 26.3 299.7 479.1 179 -238.5 1.8 291.2	22.1 306.9 1,181.9 377.7 32.5 27.0 319.3 512.8 512.8 512.8 -224.1 -7.6 349.6
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital NOPAT ROIC (%) ROIC - WACC (%) EVA DCF EBIT + Depreciation/Amortization - CAPEX - Incr. (Decr.) in Working Capital Free Cash Flow for Firm WACC Cost of Debt (Tax Adj.)	16.4 166.5 118,769 1,018.6 280.9 28.5 22.3 227.6 377.5 200 -275.7 -31.1 233.1 3.3	21.3 262.2 1,082.2 314.2 29.9 23.4 252.7 426.4 163 -178.4 -6.7 304.7 2.9	22.9 290.8 1,139.5 352.9 31.8 26.3 299.7 479.1 179 -238.5 1.8 291.2 2.9	22.1 306.9 1,181.9 377.7 32.5 27.0 319.3 512.8 189 -224.1 -7.6 349.6 2.9
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital NOPAT ROIC (%) ROIC - WACC (%) EVA DCF EBIT + Depreciation/Amortization - CAPEX - Incr. (Decr.) in Working Capital Free Cash Flow for Firm WACC Cost of Debt (Tax Adj.) Cost of Equity (COE)	16.4 166.5 118,769 1,018.6 280.9 28.5 22.3 227.6 377.5 200 -275.7 -31.1 233.1 3.3 7.5	21.3 262.2 1,082.2 314.2 29.9 23.4 252.7 426.4 163 -178.4 -6.7 304.7 2.9 8.2	22.9 290.8 1,139.5 352.9 31.8 26.3 299.7 479.1 179 -238.5 1.8 291.2 2.9 6.6	22.1 306.9 1,181.9 377.7 32.5 27.0 319.3 512.8 189 -224.1 -7.6 349.6 2.9 6.7
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital NOPAT ROIC (%) ROIC - WACC (%) EVA DCF EBIT + Depreciation/Amortization - CAPEX - Incr. (Decr.) in Working Capital Free Cash Flow for Firm WACC Cost of Debt (Tax Adj.) Cost of Equity (COE) WACC (%)	16.4 166.5 118,769 1,018.6 280.9 28.5 22.3 227.6 377.5 200 -275.7 -31.1 233.1 3.3 7.5 6.2	21.3 262.2 314.2 29.9 23.4 252.7 426.4 163 -178.4 -6.7 304.7 2.9 8.2 6.6	22.9 290.8 1,139.5 352.9 31.8 26.3 299.7 479.1 179 -238.5 1.8 291.2 2.9 6.6 5.5	22.1 306.9 1,181.9 377.7 32.5 27.0 319.3 512.8 189 -224.1 -7.6 349.6 2.9
Spread (FROE-COE) (%) Residual Income 12M RIM Target Price (W) EVA Invested Capital NOPAT ROIC (%) ROIC - WACC (%) EVA DCF EBIT + Depreciation/Amortization - CAPEX - Incr. (Decr.) in Working Capital Free Cash Flow for Firm WACC Cost of Debt (Tax Adj.) Cost of Equity (COE)	16.4 166.5 118,769 1,018.6 280.9 28.5 22.3 227.6 377.5 200 -275.7 -31.1 233.1 3.3 7.5 6.2	21.3 262.2 314.2 29.9 23.4 252.7 426.4 163 -178.4 -6.7 304.7 2.9 8.2 6.6	22.9 290.8 1,139.5 352.9 31.8 26.3 299.7 479.1 179 -238.5 1.8 291.2 2.9 6.6 5.5	22.1 306.9 1,181.9 377.7 32.5 27.0 319.3 512.8 189 -224.1 -7.6 349.6 2.9 6.7

VALUATION INDEX

26.7

30.1

19.9

6.1

(M/bp)	2014/12A	2015/12E	2016/12F	2017/12E
(Wbn)				2017/12F
Cash and Cash Equivalents	106	185	247	320
Accounts Receivables	274	283	300	314
Total Current Assets	573	674	768	868
Tangible Assets	618	636	699	736
Investment Assets	123	125	128	130
Non-Current Assets	1,003	1,062	1,123	1,161
Assets	1,576	1,736	1,891	2,029
Short-Term Debt	163	170	177	184
Account Payables	47	49	54	57
Current Liabilities	468	490	530	558
Long-Term Debt	8	9	9	9
Long-Term Allowance	14	15	16	16
Non-Current Liabilities	49	52	54	55
Liabilities	517	542	584	613
Capital Stock	41	41	41	41
Capital Surplus	131	131	131	131
Retained Earnings	1,002	1,137	1,250	1,358
Non-Controlling Interests Equity	0	0	0	0
Shareholders' Equity	1,059	1,194	1,307	1,416

STATEMENT OF FINANCIAL POSITION

2014/12A 2015/12E 2016/12F 2017/12 ROE (%) 24.0 29.5 29.5 28. ROA (%) 15.1 20.0 20.3 20.0 ROIC (%) 28.5 29.9 31.8 32.1 EBITDA/ equity (%) 54.5 49.4 50.4 49.1
ROA (%) 15.1 20.0 20.3 20.1 ROIC (%) 28.5 29.9 31.8 32.3
ROIC (%) 28.5 29.9 31.8 32.4
EBITDA/ equity (%) 54.5 49.4 50.4 49.1
EBITDA/ asset (%) 36.6 34.0 34.8 34.1
Dividend Yield (%) 2.4 2.7 3.5 3.1
Payout Ratio (%) 61.1 59.3 69.3 72.1
Total Cash Dividend (Wbn) 148 197 255 283
Cash DPS (W) 2,000 2,652 3,438 3,800
Net debt(cash)/ equity (%) 5.4 -1.3 -5.4 -9.0
Debt/ equity (%) 48.8 45.4 44.7 43.3
Net interest exp/ sales (%) 171 179 186 193
Interest coverage (X) 0.5 0.3 0.3 0.3
Current Ratio (%) 34.8 64.1 69.2 71.
Quick Ratio (%) 122.5 137.6 144.8 155.
Total shares (mn) 77 77 77 77 77
Par value (W) 500 500 500 500
Share price (W) 84,200 98,600 98,600 98,600
Market Cap (Wbn) 6,494 7,605 7,605 7,605

Rating and target price update

Company	Code	Date	Rating	Target price	
Coway	021240.KS	2015.08.05	Buy	W125,000(12M)	(won) Closing Price
		2015.05.07	Buy	W110,000(12M)	130,000 r
		2014.04.22	Buy	W100,000(12M)	Target price(12M)
					90,000
					70,000
					50,000
					'13.8 '13.11 '14.2 '14.5 '14.8 '14.11 '15.2 '15.5

NH Investment & Securities Stock Ratings

1. Rating based on a stock's forecasted absolute return over a period of 12 months from the date of publication.

- Buy: Greater than +15%
 Hold: -15% to +15%
- Sell: Less than -15%

2. Regarding listed companies under NH I&S' coverage, our stock ratings break down as follows (as of Jul 31, 2015).

• NH I&S' stock rating distribution

Buy	Hold	Sell
69.2%	29.2%	1.6%

- The stock rating on an individual company can change at irregular intervals. Our stock rating distribution is calculated on a weekly basis.

Compliance Notice

- NH I&S does not have a stake greater than or equal to 1% in Coway as of the preparation date.
 NH I&S has not provided this material to any institutional investor or other third party in advance.
- The analyst and his/her spouse do not own any securities of 'Coway' as of the preparation date. This report correctly reflects the analyst's opinion and was written without any external influence or intervention. •

Disclosures

The research is based on current public information that NH I&S considers reliable, but NH I&S does not represent it as accurate or complete and it should not be relied on as such. Furthermore, the research does not take into account particular investment objectives, financial situations or individual client needs, and NH 1&S is in no way legally responsible for future returns or loss of original capital. All materials in this report are the intellectual property of NH I&S. Copying, distributing, transmitting, transforming or lending of this material without NH I&S' consent is prohibited.